Skip to main content

Table 4 ASDAS-CRP comparison of cytokines in active-AS group responders and nonresponders after 24 months of TNF blockade, control-AS group, and healthy controls

From: IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients

     Control-AS group    
  Active-AS patients after anti-TNF (ASDAS-CRP <2.1; n = 21) Healthy controls (n = 47)
Cytokine Responders Nonresponders p valuea   p valueb   p valuec
  (ASDAS-CRP <2.1; n = 27) (ASDAS-CRP ≥2.1; n = 20)      
IL-17A (pg/ml) 2.17 (0.86–3.99) 1.04 (0.66–1.82) <0.05 1.29 (1.10–2.17) 0.07 1.57 (1.04–2.17) 0.23
IL-22 (ng/ml) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.99 0.00 (0.00–0.00) 0.71 0.00 (0.00–0.00) 0.64
IL-23 (ng/ml) 0.09 (0.03–0.21) 0.05 (0.02–0.13) 0.49 0.02 (0.01–0.06) 0.01 0.02 (0.00–0.05) <0.001
PGE2 (pg/ml) 13.03 (4.30–56.59) 45.17 (10.92–93.76) 0.10 8.13 (4.17–23.07) 0.11 7.66 (3.30–30.32) 0.33
  1. All values are expressed as the median (25–75 % interquartile range)
  2. aActive-AS group responders after 24 months of TNF blockade vs. nonresponders
  3. bActive-AS group responders after 24 months of TNF blockade vs. control-AS group (ASDAS-CRP <2.1)
  4. cActive-AS group responders after 24 months of TNF blockade vs. healthy controls
  5. AS ankylosing spondylitis, ASDAS-CRP C-reactive protein Ankylosing Spondylitis Disease Activity Score, IL interleukin, PGE2 prostaglandin E2, TNF tumor necrosis factor